VIDEO: Gene therapy improves visual acuity in patients with retinitis pigmentosa
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Christine Kay, MD, discusses MCO-010, a gene-agnostic therapy for patients with advanced retinitis pigmentosa.
Kay said the RESTORE trial met its primary endpoint of improvement in best corrected visual acuity from baseline to 52 weeks.
“The safety profile was excellent,” she said. “There were no drug-related serious adverse events. There was mild to moderate inflammation which was easily controllable with reintroduction of topical steroids.”
Collapse
Kay C. Longitudinal BCVA and safety analysis of mutation-agnostic MCO-010 optogenetic therapy for retinitis pigmentosa: Patient case from a phase 2b randomized, sham-controlled, patient- and assessor-masked clinical trial. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Read more about
Click Here to Manage Email Alerts